KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Discontinued OperationsCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesChange in TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Travere Therapeutics (TVTX) Long-Term Debt Repayments (2016 - 2022)

Travere Therapeutics (TVTX) has disclosed Long-Term Debt Repayments for 7 consecutive years, with $211.3 million as the latest value for Q1 2022.

  • For the quarter ending Q1 2022, Long-Term Debt Repayments changed N/A year-over-year to $211.3 million, compared with a TTM value of $211.3 million through Dec 2022, changed N/A, and an annual FY2025 reading of $68.9 million, changed N/A over the prior year.
  • Long-Term Debt Repayments was $211.3 million for Q1 2022 at Travere Therapeutics, up from -$39.2 million in the prior quarter.
  • Across five years, Long-Term Debt Repayments topped out at $211.3 million in Q1 2022 and bottomed at -$39.2 million in Q4 2018.